Posted on 25 August 2014.
The University College Cork (UCC) Centre for Research in Vascular Biology has developed a medical device that promotes the bypass of arterial obstructions, potentially removing the need for open-heart surgery.
Director of the centre Prof Noel Caplice, himself a practising interventional cardiologist, led the research project in UCC, which included collaborators in the Mayo Clinic in the US.
Caplice began this project in the Mayo Clinic, where he and his colleagues designed a mesh device that could be attached to a stent, which could deliver millions of cells and promote bypass in an obstructed artery.
Since his return to UCC in 2005, Caplice has further developed this technology so it can be delivered using a catheter.
The vascular cell delivery device can be inserted via a keyhole procedure through the artery to the site of the obstruction. The implanted device can then promote micro-bypass of the obstruction over a four-week period, resulting in the return of normal heart function and a recovery of full exercise capacity.
The device has been tested successfully in a large animal model with similar-sized arteries to humans, and the next phase of this research will involve testing on patients who require bypass surgery but have been deemed unfit to undergo the procedure.
About 3m open-heart coronary bypass and peripheral artery bypass operations are carried out each year around the world. However, around 20pc of patients who need this surgery are unable to undergo the procedure due to poor status of arteries or a co-existing illness making the risk too great.
“If reproduced in humans, this device would offer an alternative to open surgical bypass operations with implications for treatment of patients who are currently inoperable,” said Caplice.
“It also has the potential to reduce costs and time spent in hospital,” he added.
This research, which could be a major step forward in the treatment of coronary disease, has been published in the journal Biomaterials.
Posted in Healthcare, Medical Research, News, R&D News
Posted on 30 July 2014.
Irish biotech start-up Inform Bioscience has signed a licence agreement with the Mayo Clinic in the US to acquire biomarkers for developing a prognostic test to detect pre-eclampsia in pregnancy.
Prognostic tests provide advance warnings of an illness or condition. There are currently no such tests to detect pre-eclampsia, a potentially fatal condition for a pregnant woman and her unborn baby.
In the most severe cases, pre-eclampsia can progress to eclampsia, which often results in seizure, stroke, coma and death. The condition is diagnosed by symptoms that are non-specific to pre-eclampsia and often exhibit only when the condition is already full blown.
Now, the Inform Bioscience team based in Cork plans to develop a simple urine test, employing biomarker technology developed by Mayo Clinic nephrologist Dr Vesna Garovic. The test has the potential to revolutionise prenatal care programmes globally.
Speaking of the licence agreement, Charles Garvey, CEO of Inform Bioscience said, “Inform Bioscience is bridging the gap between the discovery of quality technology and its commercialisation.
“Today is a key milestone in the development of Inform Bioscience and demonstrates our capacity to work with and integrate the work of world-class research institutions, such as Mayo Clinic and the Biomedical Diagnostics Institute (BDI) at Dublin City University, to bring innovative new technologies to market.”
Posted in Innovation, Medical Research, News, R&D Investment, R&D News
Posted on 10 April 2014.
Early stage medical treatments and devices – invented at the Mayo Clinic in the US – are to be developed into ready for market products by Irish academic institutions under a new agreement to be signed this morning.
It is hoped the five year plan will lead to the setting up of 10 new spin-out companies and the creation of dozens of jobs.
For the past 150 years, the non-profit Mayo Clinic in the US has been a world leader in medical treatment and research.
But according to the clinic, developing a good idea from early stage basic research into a ready for market product is expensive and difficult to fund in the US.
The Taoiseach will today witness the signing of an agreement that will see the Mayo Clinic partner with EnterpriseIreland, which has an established commercialisation fund and expertise in the area.
The clinic will hand over 20 promising ideas for new medical technologies and EnterpriseIreland will provide €12m in funding and experts in universities and academic institutions here to develop them for market.
The first project – a device for treating acute pancreatitis – is already being developed at NUI Galway.
It is hoped the unique partnership will lead to the creation of 10 spin-out companies, and as a consequence the creation of dozens of jobs
Posted in Medical Research, R&D News